New Progress in Study on Mechanism of Lianhua Qingwen Capsules for Treatment of COVID-19 – About Your Online Magazine

SHIJIAZHUANG, China, February 23, 2021 / PRNewswire / – Recently, Prof. Caisheng Wu and Prof. Yifeng Chai from the School of Pharmacy, Xiamen The university has made further progress in the study of pharmacologically active ingredients and the mechanism of Lianhua Qingwen capsules, developed and produced by Yiling Pharmaceutical, in the prevention and treatment of COVID-19. The result of the study, “Screening of Anti-COVID-19 Active Pharmacological Ingredients from Traditional Chinese Medicine Lianhua Qingwen Capsules Based on Human Exposure and Biochromatography ACE2”, was published in the leading journal of pharmacology, Acta Pharmaceutica Sinica B. This is the most recent evidence of the prevention and treatment of COVID-19 by Chinese medicine Lianhua Qingwen.

This study was based on HRMS and non-targeted smart data mining techniques, and comprehensively analyzed the components of Lianhua Qingwen capsules in human plasma and urine after multiple administrations, synthesized a new biochromatographic stationary phase ACE2 and tracked the potential components directed to ACE2 Extracts from Lianhua Qingwen capsules and human urine samples. The experimental results showed that 85 relevant components of Lianhua Qingwen have been successfully identified in humans after multiple administrations, and a small number of components have been selected to verify the binding capacity of ACE2 by SPR analysis. The components Amygdalin, Prunasin, Glycyrrhizic Acid, Forsythoside A, Forsythoside I, Rhein and Aloe-emodin, all showed binding affinity for ACE2. It should be noted that these components not only showed good affinity for ACE2, but can also bind effectively to the contact surface of the ACE2 and S protein complex, as confirmed by computer-aided docking results. These ACE2 binding components can inhibit Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by effectively affecting the binding between ACE2 and S protein, providing an experimental basis for the prevention and treatment of Coronavirus Disease 2019 (COVID -19) with Lianhua Qingwen capsules.

Lianhua Qingwen Capsules is an innovative Chinese medicine developed and produced by Yiling Pharmaceutical, which is mainly used to treat colds, flu and other illnesses. Since the COVID-19 outbreak, Lianhua Qingwen capsules have been recommended by the official Chinese “Diagnostic and Treatment Protocol for COVID-19” (Trials 4th-8th Edition) and used in admission hospitals designated for COVID-19 in China. The drug is currently approved for commercialization in 21 countries and regions, including Canada, Russia, Singapore and Kuwait.

The results of the study published in this publication are the first elaboration of information about the human being at Vivo composition of Lianhua Qingwen capsules, providing a theoretical chemical and pharmacological basis for the study of its pharmacologically active ingredients and mechanism of action in 2019 anti-virus disease (COVID-19), and further elaboration of how Lianhua Qingwen human works at Vivo perspective, which is an extension of the experimental studies and clinical evidence of Chinese medicine for the treatment of COVID-19.

SOURCE Yiling Pharmaceutical

Paula Fonseca